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to their visit to General Practitioner. Study population I: Before the implementation 
of guidelines and the educational leaﬂ et. Study population II: After the implementation 
of guidelines and the educational leaﬂ et. Cross-sectional analysis and descriptive 
analyses was performed using the Statistical Package for Social Sciences (SPSS). 
RESULTS: The total number of antibiotic prescriptions for patients suffering from 
U.R.T.I. including sore throat was signiﬁ cantly reduced in the intervention group 
(67% reduction). CONCLUSIONS: A multi-dimensional interventional approach for 
reducing antibiotic prescription in U.A.E. clinics resulted in a signiﬁ cant positive 
outcome. The signiﬁ cant reduction in antibiotic prescriptions indicates the willingness 
of physicians to follow guidelines and the willingness of patients to respond to edu-
cational information.
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OBJECTIVES: To estimate the impact of ocular hypertension (OHT)/primary open-
angle glaucoma (POAG) on health status and quality-of-life. METHODS: Classiﬁ ca-
tion of disease state followed European Glaucoma Society guidelines. Health status 
was based upon the Health Utility Index Mark 3 (HUI3) The National Eye Institute 
25-Item Visual Function Questionnaire (NEI-VFQ-25) was self-administered. Utility 
scores were compared to a normal population matched by age and gender. Differences 
in health impact and quality-of-life between the different disease states were assessed. 
RESULTS: 154 patients were enrolled (27 OHT, 43 early, 35 moderate, 49 advanced 
POAG) from 15 centers in Germany, 137 were diagnosed 35 years ago. Average age 
was 67 ± 11 and 57% were female. 23% of patients had cardiovascular co-morbidity, 
45% history of cataract, 45% hypertension, 18% diabetes, and 10% hypotension. 
Differences in baseline characteristics were seen for age (60, 63, 69, 72 years), history 
of cataract (24%, 25%, 54%, 62%), employment status (43%, 24%), and hypoten-
sion (14%, 0%, 14%, 15%). The HUI3 score for OHT, early, moderate and advanced 
POAG was 0.87 ± 0.09, 0.85 ± 0.15, 0.75 ± 0.23 and 0.58 ± 0.32, respectively. There 
was no difference in the health utility score for patients with OHT, early POAG and 
the normal population. Patients with moderate and advanced POAG were lower by 
0.06 ± 0.24 and 0.19 ± 0.28, signiﬁ cantly different from OHT and early POAG (P < 
0.01). The NEI-VFQ-25 for OHT and early POAG gave ocular symptoms and mental 
health the lowest scores. For moderate POAG the lowest scores were for driving, 
ocular symptoms, mental health, role limitation and peripheral vision. For advanced 
POAG, all domains, except color vision, were affected. CONCLUSIONS: Disease 
progression in glaucoma affects not only vision, but also quality-of-life. Whereas OHT 
and early POAG have little effect on quality-of-life, moderate and advanced POAG 
do. These ﬁ ndings can improve doctor-patient relationships, addressing quality-of-life 
issues for different glaucoma disease states.
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OBJECTIVES: The aim of the current study was to develop an algorithm to map the 
symptom domain of the Impact of Dry Eye on Everyday Life (IDEEL) questionnaire 
to a preference based utility index. METHODS: Data from an IDEEL psychometric 
validation study including 210 participants (130 dry eye patients, 32 Sjogren’s patients 
and 48 controls) were used to estimate the algorithm. Participants completed the 
IDEEL, EQ-5D and SF-36 at 2 time points; the ﬁ rst time point was used to estimate 
the algorithm and the second to validate the algorithm. The mapping work was 
preceded by determining bivariate correlations between the IDEEL items and each 
utility index (EQ-5D and SF-6D), and then examining the sensitivity of each index to 
variability in dry eye severity. Initial items were selected based on levels of missing 
data, ﬂ oor and ceiling effects and correlations with the utility index. Items were then 
included in an OLS regression model with age and gender interaction terms. Following 
the item analysis the same procedures were applied to a domain level analysis. 
RESULTS: Based on the criteria outlined above, the SF-6D was selected as the utility 
index for the mapping algorithm. The ﬁ nal OLS regression model contained 2 IDEEL 
symptoms items and age, and explained 28% of the variance in SF-6D utility values; 
root mean squared error (RMSE) = 0.105. As the SF-6D data included few bounded 
or censored estimates Tobit and CLAD models were not estimated. The validation 
data set demonstrated a signiﬁ cant correlation between the predicted and observed 
SF-6D utility values (r = 0.53, p < 0.001). CONCLUSIONS: This algorithm forms a 
good basis to estimate utility values from the IDEEL for inclusion in cost-effectiveness 
analysis.
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OBJECTIVES: To identify and review published utility estimates in atopic dermatitis 
(AD), and to catalogue the methods of utility assessment, patient populations studied, 
and economic evaluations incorporating the utility estimates. METHODS: A system-
atic search and review of the published literature, including health technology assess-
ments, in AD was performed. Utility search terms were those recommended by NICE 
in the UK Publications were limited to English language only, from 1999 through 
2010. RESULTS: Fourteen studies presenting 15 different sets of utility data in AD 
(one study used two separate methods to generate estimates) were identiﬁ ed. These 
14 studies are summarized in 11 separate publications (one health technology assess-
ment describes three otherwise unpublished utility studies). All studies but one present 
utility estimates (vs changes in utility). Two studies present a single utility estimate 
for AD. One study presents utility estimates for controlled vs. uncontrolled AD. All 
other studies present utility estimates by AD severity (e.g., clear, mild, moderate, 
severe), although only two studies link AD severity directly to IGA scores. Two studies 
present utility estimates for children. AD utilities have been collected or applied in 
economic evaluations in Canada, Germany, Sweden, the UK, and the US. Utilities in 
AD have been collected directly using SG, TTO, VAS (with the VAS results being 
converted into utilities for use in economic evaluations using an algorithm that reﬂ ects 
attitudes towards risk), and using the EQ5D. Three studies have generated utility 
estimates based on applying two separate published algorithms to SF-12 or SF6D data. 
Five sets of utility data have been used in economic evaluations. CONCLUSIONS: 
There are several published studies presenting utility estimates in AD; however, they 
vary greatly in terms of methods employed. Economic evaluations in AD, the results 
of which are sensitive to uncertainty in utility inputs, have relied on various 
estimates.
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OBJECTIVES: The assessment of quality of life (QoL) in dermatology is becoming 
increasingly popular as demonstrated by the creation and development of numerous 
questionnaires for the principal diseases of the skin. Paradoxically, although cosmetic 
dermatology is rapidly developing, there is no questionnaire to assess the impact of 
these products on the QoL of the women that use them. There was therefore a need 
for the creation of the Cosmeti QoL. METHODS: The questionnaire was developed 
using rigorous methodology in accordance with international standards in terms of 
quality of life. a literary review and face-to-face interviews were conducted to identify 
the concepts that preoccupied women over 25 years of age. Twenty-two items were 
identiﬁ ed after the ﬁ rst transcription; this was reduced to 12 items after an initial 
analysis making it easier to use. a representative population of 1002 French women 
aged 25 years and over, was put together by the CSA Santé institute using the quota 
method. They were given the Cosmeti QoL; the lower the score the better the Qol. 
RESULTS: The questionnaire is easy to use, good comprehension of the questions was 
observed. The Cosmeti QoL score is correlated to age. An improved QoL is seen in 
women who frequently use a moisturizing cream (13.7 vs. 14.23, P < 0.001). Sensitive 
skin resulted in poorer QoL (14.77 vs. 13.34 P < 0.001), the frequency of episodes 
of sunburn during childhood also reduced the QoL (14.96 vs. 13.86 P < 0.001). In 
the population over 65 years of age, the QoL was superior in women who claimed to 
use cosmetic, anti-wrinkle, or moisturizing products on a regular basis. CONCLU-
SIONS: The Cosmeti QoL scale, which is essentially based on the women’s point of 
view, is a valid, pertinent, and well accepted tool enabling the assessment of quality 
of life perceived through the skin.
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OBJECTIVES: No consensus on deﬁ nition of plaque psoriasis severity currently exists. 
Although standard measures of psoriasis severity are commonly used in clinical prac-
tice, they are not consistent and rarely based on patient assessment. The objective was 
to develop an instrument assessing patient and physician perceptions of psoriasis 
severity and treatment effect. METHODS: Semi-directive exploratory interviews were 
conducted with 20 patients with mild to severe plaque psoriasis, and with 20 derma-
tologists. Interviews’ transcripts were analyzed to extract and organise into models 
the criteria used by patients and physicians to evaluate psoriasis severity and treatment 
beneﬁ t. Items were generated using patient words for each concept considered relevant 
by both patients and dermatologists. The instrument was developed in parallel for 
patients and for physicians, tested for relevance and comprehension on 5 patients and 
5 physicians, and revised accordingly. The new version was tested on 5 new patients 
and 5 new physicians and revised to create a pilot version. a dermatologist advisory 
board was involved at each step of the instrument development. RESULTS: The test 
instrument consisted in 31 items including area involvement, lesion location, signs and 
symptoms (frequency, duration of lesions, joint involvement), treatment history, 
quality of life impact, rapidity and duration of treatment beneﬁ t, and patient satisfac-
tion. The instrument was globally well-accepted by patients and physicians; few 
modiﬁ cations were made. a 32-item pilot version resulted from the comprehension 
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tests. CONCLUSIONS: The instrument constitutes a single tool to assess both patient 
and physician perceptions of psoriasis severity and treatment effect. The availability 
of a shared instrument may improve treatment decision-making, reconciliating patient 
and physician perceptions. An observational study with 100 dermatologists and 561 
patients is planned to assess agreement between patient and clinician perceptions; 
scoring and psychometric properties will also be validated.
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OBJECTIVES: This research has been driven by the need for a quality of life (QoL) 
instrument that speciﬁ cally assesses physical appearance. The BeautyQol instrument 
is a multi-dimensional, self administered questionnaire, which has been in develop-
ment for over three years in 16 languages. METHODS: In the item generation phase, 
semi directive interviews were conducted in 309 subjects. In the second phase an 
acceptability study was conducted on 874 subjects in France, UK, Germany, Spain, 
Sweden, Italy, Russia, USA, Brazil, Japan, India (Hindi and English) China and South 
Africa (Zulu, Sotho and English). In the third phase, a total of 3231 subjects were 
recruited. to complete the BeautyQoL questionnaire, a skin clinical checklist, SF-36 
and a socio-demographic questionnaire. a re-test has been carried out at 8 days on a 
subgroup of 652 subjects. The database was randomly divided into two subgroups 
and analyzed using a Rash analysis. Psychometric properties, construct validity, repro-
ducibility, internal and external consistency were tested. RESULTS: From the item 
generation phase, 62 questions were selected. General acceptability was very good in 
the 16 cultures, with a very low rate of no answers. The validation phase reduced the 
questionnaire in 44 questions structured in ﬁ ve dimensions explaining 76.7% of the 
total variance: Social Life, Self conﬁ dence, Psychological life, Vitality and Seduction. 
Internal consistency was high (Cronbach alpha coefﬁ cients between 0.932 and 0.978). 
Reproducibility at 8 days was satisfactory in all dimensions. External validity testing 
revealed that BeautyQol scores correlated signiﬁ cantly with all SF-36 scores except 
for Physical Function. Mean completion time was 7 minutes (median:5 minutes). 
CONCLUSIONS: These results demonstrate the validity and reliability of the Beau-
tyQol questionnaire as the very ﬁ rst international instrument speciﬁ c to physical 
appearance. It is expected that BeautyQoL will be an instrument that will measure 
QoL affected by cosmetic products, techniques and agents that alter physical 
appearance.
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DISCREPANCY IN PATIENT AND PHYSICIAN GLOBAL ASSESSMENTS 
OF DERMATOLOGIC DISEASES
Tabolli S, Spagnoli A, Sampogna F, Pagliarello C, Abeni D, Paradisi A
IDI IRCCS Rome, Rome, Italy
OBJECTIVES: To investigate discrepancy in the perception of dermatologic diseases 
(DD) severity between patients and physicians. METHODS: A descriptive study was 
performed: 2459 patients with DD rated their level of disease severity on a ﬁ ve level 
scale: very mild, mild, moderate, severe, very severe (PtGA). Physician global assess-
ment (PhGA) was performed on the same scale. Fifty three physicians were involved 
in an out-patient setting for three weeks (March 2010) in a dermatologic research 
hospital, Rome, Italy. RESULTS: Patients were predominantly females (59%), with 
an high education and the majority were employed; mean age was 45.9 ± 18.5 for 
females and 44.5 ± 18 for males. No discrepancy between PhGA and PtGA was 
observed in 37% of cases; PtGA under-rated compared to the physician in 35%; and 
PtGA over-rated relative to the physicians in 28%. Statistically signiﬁ cant differences 
were observed between PtGA and PhGA in each of the ﬁ ve levels of judgement (P < 
0.001). Higher percentages of patients, in respect to physicians, reported very mild, 
severe and very severe evaluations. Physicians tended to overestimate for mild and 
moderate levels. Differences were observed between male and female physicians in the 
severity judgement, reaching a statistically signiﬁ cant difference for the very mild level 
(P < 0.001) where females were more represented. CONCLUSIONS: The perceived 
severity disease in DD was different between patients and physicians and it was dif-
ferent in patients in respect to sex. Only for very mild DD there was a difference in 
PhGA between males and females, with males underestimating the severity.
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OBJECTIVES: To review the available vision-related QoL instruments that could be 
used to investigate the consequences of refractive cataract surgery, in particular the 
beneﬁ t of spectacle independence. METHODS: A literature review was undertaken 
on PubMed and Embase databases using keywords “Refractive Surgical Procedures”, 
“Refractive Errors”, “Refractive”, “Questionnaire”, and “QoL”. Questionnaires were 
selected if they were developed for cataract or refractive surgery, based on the reading 
of the manuscript abstract. a further search was performed on PubMed, Embase and 
ProQolid databases to obtain information on development and psychometric valida-
tion of the questionnaires. Authors were contacted by email if missing data were 
identiﬁ ed from the published literature. Main characteristics of the questionnaires 
were described including number of items, targeted population, mode of administra-
tion, response scale, languages, and number of publications. Development methodol-
ogy was reviewed (literature review, clinician input, patient input and comprehension 
test). Psychometric properties were examined (e.g. domain description, scoring algo-
rithm, internal consistency, clinical validity, reproducibility, responsiveness). The 
above characteristics were then examined in light of the US FDA’s “Guidance for 
Industry Patient-Reported Outcome Measures: Use in Medical Product Development 
to Support Labeling Claims”. RESULTS: A total of 141 abstracts were reviewed and 
14 questionnaires were identiﬁ ed. Four instruments had both a solid development 
methodology and good psychometric properties: the CatQuest (Cataract Question-
naire), the NEI-RQL-42 (US National Eye Institute Refractive Error QoL instru-
ment-42), the NEI-VFQ-25 (US National Eye Institute Visual Function 
Questionnaire-25) and the RSVP (Refractive Status and Vision Proﬁ le). When includ-
ing the ability to assess vision-related QoL with the beneﬁ t of not wearing glasses, it 
appeared that the NEI-RQL-42 was one of the best candidates, although the beneﬁ ts 
of spectacle independence could be more deeply explored. CONCLUSIONS: Accord-
ing to this literature review, the NEI-RQL-42 could be considered as one of the best 
instruments to capture refractive vision-related QoL consequences after cataract 
surgery.
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OBJECTIVES: Estimates of the lifetime prevalence of external genital warts (EGW) 
and genital herpes in the European Union range from 0.47% to 1.52% and 0.59% 
to 1.43% respectively. The aim here is to assess, for the ﬁ rst time, the impact of the 
experience on current health related quality of life at the general population level. 
METHODS: Data are from the 2008 National Health and Wellness Survey. This is 
an internet-based survey carried out in the UK, France, Spain, Italy and Germany. 
From a total of 53,524 respondents, 521 indicated they had experienced EGW and 
520 genital herpes. Only 63 had experienced both conditions. The regression analysis 
is based on health state utilities (score 0–100) from the SF-6D. The independent 
variables included binary variables for the presence/absence of EGW and genital 
herpes, socio-demographic characteristics, health risk factors (e.g., body mass index) 
and the Charlson Comorbidity Index (CCI). RESULTS: The experience of EGW and 
genital herpes had a substantial negative impact on utility scores. The impact was 
signiﬁ cant at conventional decision levels: EGW—2.47 (95% CI: −3.58–−1.36), genital 
herpes −3.52 (95%CI: −4.63–−2.71) and EGW and genital herpes −5.00 (95%CI: 
1.76–8.25). The impact of EGW and genital herpes experience was similar to the 
negative impact of BMI for persons who were underweight, obese and morbidly obese 
and the CCI (−2.53;95%CI: −2.65–−2.41). Age, education and income all had a posi-
tive and signiﬁ cant impact on HRQoL. CONCLUSIONS: This is the ﬁ rst time the 
lifetime experience of two of the most prevalence sexually transmitted infections (STIs) 
on current HRQoL has been assessed. The results point to the continuing impact of 
this experience, with herpes having a marginally greater impact than EGWs. The 
HRQoL deﬁ cit is most apparent for those who have experienced both STIs. 
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REAL-LIFE DOSING OF BIOLOGICS IN PLAQUE PSORIASIS—A GERMAN 
SURVEY
Klesse M, Wolbring F
Janssen-Cilag GmbH, Neuss, Germany
OBJECTIVES: Evaluation of use, dose distribution, and dosing rationale of biologic 
treatments in plaque psoriasis within private practices and hospitals in Germany. 
METHODS: Fully structured Online Questionnaire using Umfragecenter® software. 
Panel participants were selected by DocCheck Medical Services using their MediAccess 
Pool. Survey was done in December 2009. 100 dermatologists (60 in private practices, 
40 in hospitals) were included in the survey. Inclusion criterion: currently treating at 
least two psoriasis patients with biologics, at least one patient on adalimumab, etan-
ercept or inﬂ iximab. RESULTS: Each surveyed dermatologist treated approximately 
100 psoriasis patients per quarter. In private practice about 10% of these patients 
were treated with a biologic, while in hospitals about 23% received biologic treatment. 
About 40% of the patients receiving a biologic suffered from psoriatic arthritis as 
well. Distribution of the different biologics used was as follows: etanercept 37%, 
adalimumab 33%, inﬂ iximab 20%, and ustekinumab 10%. Only minor differences 
in those proportions were observed between private practices and hospitals. In about 
80% of all cases, used dosing for each biologic conformed to the respective label. In 
other cases, increased dosages were observed, for example: 12% of adalimumab 
patients received 40 mg weekly, 17% of etanercept patients being treated longer than 
